A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
← catalyst calendarNCT06874010 · readout ≤ 134 d
Sponsored by Design Therapeutics, Inc. (industry) · DSGN — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
20estimated
Sites
3
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2025 | estimated | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Friedreich Ataxia
Intervention
- Drug: DT-216P2
Primary outcome
what the primary-completion date above is the date OFFrequency of treatment-emergent adverse events (TEAE)
measured Up to Week 12
Permalink · DSGN's whole pipeline · Catalyst calendar · Every registered study · What changed